Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition - Narrative (Details)

v3.24.3
Asset Acquisition - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Aug. 13, 2024
Mar. 28, 2024
Mar. 27, 2024
Oct. 31, 2024
Apr. 30, 2024
Sep. 30, 2024
Oct. 08, 2024
Common stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Conversion of stock, issuance(in shares)     6,585,314        
Almata Transaction And March 2024 Financing              
Asset Acquisition, Contingent Consideration [Line Items]              
Shares issuable in common stock (in shares) 349            
Almata Transaction And March 2024 Financing | Common stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Conversion of stock, issuance(in shares) 8,648,244            
Almata Transaction And March 2024 Financing | Series C Preferred Stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Shares issuable in common stock (in shares)     2,412        
Shares converted (in shares)     2,063     8,648  
AlmataBio Transaction              
Asset Acquisition, Contingent Consideration [Line Items]              
Common stock shares issued (in shares)     171,605        
Shares issuable in common stock (in shares)     2,412        
Payments to acquire productive assets   $ 7,500     $ 7,500 $ 7,500  
AlmataBio Transaction | Common stock              
Asset Acquisition, Contingent Consideration [Line Items]              
Conversion of stock, issuance(in shares)     2,062,930        
AlmataBio Transaction | Milestone One              
Asset Acquisition, Contingent Consideration [Line Items]              
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial   5,000          
AlmataBio Transaction | Milestone One | Subsequent Event              
Asset Acquisition, Contingent Consideration [Line Items]              
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial             $ 5,000
Payments of merger related costs       $ 5,000      
AlmataBio Transaction | Milestone Two              
Asset Acquisition, Contingent Consideration [Line Items]              
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial   $ 15,000          
AlmataBio Transaction | Milestone Two | Subsequent Event              
Asset Acquisition, Contingent Consideration [Line Items]              
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial             $ 15,000